NCT04802759: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

NCT04802759
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have had disease progression during or after first- or second-line hormonal therapy for locally advanced or metastatic disease; Patients must have had at least one line of therapy that contained a CDK4/6 inhibitor
Exclusions: Patients with prior treatment of cytotoxic chemotherapy for metastatic breast cancer; Patients with symptomatic, untreated, or actively progressing central nervous system (CNS) metastases; Patients with a history of leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04802759

Comments are closed.

Up ↑